Menu

SEE 2024 - Volume 40 A & B

  • Claim Credits by 1/31/2025
  • Online Activity
Credits Available: CME UP TO 60 CME (2 ISSUES), AANA

This is a preorder. Volume 40A will be available late January 2024. Volume 40B will be available July 2024.

Don't have time to read numerous journals? Discover emerging knowledge from the latest literature with Summaries of Emerging Evidence (SEE)....  Read More +




Item Details

The American Society of Anesthesiologists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Anesthesiologists designates this enduring material for a maximum of 60 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification in Anesthesiology® and MOCA® are registered certification marks of the American Board of Anesthesiology®. MOCA 2.0® is a trademark of the American Board of Anesthesiology®.

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

For information on other accreditations, contact ASA Member Services at (847) 825-5586.

The 2024 editions are currently available for presale. Volume 40A will be available in January 2024. Volume 40B will be available in July 2024.

After successfully completing this activity, the learner will be able to:

  • Explain emerging concepts in anesthesia practice, as presented in the current literature
  • Discuss the impact of emerging research on clinical practice
  • Utilize this information to enhance his or her practice
This activity is intended for anesthesiologists, anesthesiology residents, and members of the anesthesia care team.

Summaries of Emerging Evidence Editorial Board 

Wade A. Weigel, MD, FASA, Editor-in-Chief
Seattle, Washington

Neil A. Hanson, MD, Medical Editor
Edina, Minnesota

Alyssa B. Brzenski, MD, FASA
San Diego, California

Destiny F. Chau, MD
Little Rock, Arkansas

Gloria Cheng, MD
Dallas, Texas

Sung "Jason" Chi, MD
Mountain View, California

Bianca M. Conti, MD
Baltimore, Maryland

Natalie F. Holt, MD, MPH
Aberdeen, South Dakota

Aaron N. Primm, MD, FASA
New York, New York

Amy Robertson, MD
Nashville, Tennessee

Naileshni S. Singh, MD
Sacramento, California

ASA Staff: Kari L. Lee, Senior Managing Editor; Ginger Clark, Managing Editor; Rachel Winokur, Senior Editor; Mark Grant, MD, PhD, Director of Practice Guidelines

The American Society of Anesthesiologists remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of the American Society of Anesthesiologists to eliminate all situations of potential conflict of interest, but rather to enable those who are working with the American Society of Anesthesiologists to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the educational activity course director/chair to ensure that such situations are properly evaluated and, if necessary, resolved. The American Society of Anesthesiologists educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all American Society of Anesthesiologists accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities.

The following SEE faculty, staff, and/or planning committee members have indicated that they have relationships with ineligible companies to disclose:

Ginger Clark
Merck & Co, Inc—Stock
Organon & Co —Stock

All relevant financial relationships for this activity have been mitigated.

All other planners, faculty, and staff have reported no relevant financial relationships with ineligible companies to disclose.

Internet connection.

Web browser: Google Chrome, Microsoft Edge, Mozilla Firefox, or Safari, updated within the last 3 years.

SEE 2024 - Volume 40 A & B
SEE 2024 Products
Select
SEE 2024 Products
select